XML 118 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Operating activities:      
Net (losses) earnings $ 8,207 $ 2,945 $ (482)
Adjustments to reconcile net (losses) earnings to net cash provided by operating activities:      
Depreciation, depletion and amortization 16,641 10,654 13,599
Gains on sales of property (1,400) (1,240) (594)
Impairment of oil and natural gas properties 0 0 3
Provision for doubtful accounts (12) (150) 78
Stock-based compensation expense 478 255 0
Deferred income taxes 2,085 936 (3,840)
Net change in fair value contracts 23 (2) 27
Gain on dissolution of AREC (573) 0 0
Impairment of investments in unconsolidated affiliates 0 0 2,500
Loss on deconsolidation of subsidiary 0 0 3,505
Changes in assets and liabilities:      
Accounts receivable (8,373) 36,350 (34,935)
Accounts receivable/payable, affiliates (24) 24 271
Inventories (3,628) (10,587) 878
Income tax receivable (165) (1,087) 1,418
Prepayments and other current assets (2) (293) 831
Accounts payable 31,795 (10,252) 44,790
Accrued liabilities 1,154 1,744 (991)
Other 693 1,717 (962)
Net cash provided by operating activities 46,899 31,014 26,096
Investing activities:      
Property and equipment additions (35,743) (11,731) (2,644)
Asset acquisitions (5,624) (10,272) 0
Proceeds from property sales 3,680 2,038 720
Proceeds from sales of AREC assets 0 0 2,775
Proceeds from dissolution of AREC 998 0 0
Insurance and state collateral (deposits) refunds 652 830 (1,067)
Net cash used in investing activities (36,037) (19,135) (216)
Financing activities:      
Principal repayments of finance lease obligations (1,697) (495) (118)
Dividends paid on common stock (3,976) (3,711) (3,711)
Net cash used in financing activities (5,673) (4,206) (3,829)
Increase in cash and cash equivalents, including restricted cash 5,189 7,673 22,051
Cash and cash equivalents, including restricted cash, at beginning of period 117,066 109,393 87,342
Cash and cash equivalents, including restricted cash, at end of period $ 122,255 $ 117,066 $ 109,393